Increased pulmonary tumor necrosis factor alpha, interleukin-6 (IL-6), and IL-17A responses compensate for decreased gamma interferon production in anti-IL-12 autovaccine-treated, Mycobacterium bovis BCG-vaccinated mice

Clinical and Vaccine Immunology

Volumn 18, Issue 1, 2011, Pages 95-104

  Freches, Danielle ^a   Romano, Marta ^a   Korf, Hannelie ^a   Renauld, Jean Christophe ^b   Van Snick, Jacques ^b   Uyttenhove, Catherine ^b   Huygen, Kris ^a  

^a SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOVACCINE; BCG VACCINE; CONCANAVALIN A; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; NEUTRALIZING ANTIBODY; OVALBUMIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BCG VACCINATION; COLONY FORMING UNIT; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; LUNG; MOUSE; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SPLEEN; TH2 CELL;

ANIMALS; AUTOVACCINES; BCG VACCINE; DOWN-REGULATION; FEMALE; IMMUNIZATION; INTERFERON-GAMMA; INTERLEUKIN-12; INTERLEUKIN-17; INTERLEUKIN-6; LUNG; MICE; MICE, INBRED C57BL; MYCOBACTERIUM BOVIS; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 78650911621     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00352-10     Document Type: Article

References (44)

1. Aggarwal, S., N. Ghilardi, M. H. Xie, F. J. de Sauvage, and A. L. Gurney. 2003. Interleukin-23 promotes a distinct CD4+ cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 278:1910-1914.
2. Alexander, J., et al. 1994. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1:751-761.
3. Andersen, P., B. Gicquel, and K. Huygen. 2004. Tuberculosis vaccine science, p. 885-898. In W. N. Rom and S. M. Garay (ed.), Tuberculosis, 2nd ed. Lippincott Williams & Wilkins, Philadelphia, PA.
4. Bean, A. G., et al. 1999. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J. Immunol. 162:3504-3511.
5. Bruns, H., et al. 2009. Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans J. Clin. Invest. 119:1167-1177.
6. Cooper, A. M., et al. 1993. Disseminated tuberculosis in interferon-gamma gene-disrupted mice. J. Exp. Med. 178:2243-2247.
7. Cooper, A. M., J. Magram, J. Ferrante, and I. M. Orme. 1997. Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with Mycobacterium tuberculosis. J. Exp. Med. 186:39-45.
8. Cooper, A. M., et al. 1995. The role of IL-12 in acquired immunity to Mycobacterium tuberculosis infection. Immunology 84:423-432.
9. Cooper, A. M., A. Solache, and S. A. Khader. 2007. Interleukin-12 and tuberculosis: an old story revisited. Curr. Opin. Immunol. 19:441-447.
10. Demoulin, J. B., et al. 1996. A single tyrosine of the interleukin-9 (IL-9) receptor is required for STAT activation, antiapoptotic activity, and growth regulation by IL-9. Mol. Cell. Biol. 16:4710-4716.
11. Dieli, F., et al. 2003. Characterization of lung γδ T cells following intranasal infection with Mycobacterium bovis bacillus Calmette-Guérin. J. Immunol. 170:463-469.
12. Espevik, T., and J. Nissen-Meyer. 1986. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J. Immunol. Methods 95:99-105. (Pubitemid 17196641)
13. Flynn, J. L., et al. 1995. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2:561-572.
14. Flynn, J. L., et al. 1995. IL-12 increases resistance of BALB/c mice to Mycobacterium tuberculosis infection. J. Immunol. 155:2515-2524.
15. Forbes, E. K., et al. 2008. Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice. J. Immunol. 181:4955-4964.
16. Happel, K. I., et al. 2005. Pulmonary interleukin-23 gene delivery increases local T-cell immunity and controls growth of Mycobacterium tuberculosis in the lungs. Infect. Immun. 73:5782-5788.
17. Harris, J., and J. Keane. 2010. How tumour necrosis factor blockers interfere with tuberculosis immunity. Clin. Exp. Immunol. 161:1-9.
18. Hauer, A. D., et al. 2005. Blockade of interleukin-12 function by protein vaccination attenuates atherosclerosis. Circulation 112:1054-1062.
19. Hoeve, M. A., et al. 2006. Divergent effects of IL-12 and IL-23 on the production of IL-17 by human T cells. Eur. J. Immunol. 36:661-670.
20. Huygen, K., et al. 1992. Spleen cell cytokine secretion in Mycobacterium bovis BCG-infected mice. Infect. Immun. 60:2880-2886.
21. Keane, J., et al. 2001. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N. Engl. J. Med. 345:1098-1104.
22. Khader, S. A., et al. 2007. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat. Immunol. 8:368-377.
23. Khader, S. A., and A. M. Cooper. 2008. IL-23 and IL-17 in tuberculosis. Cytokine 41:79-83.
24. Khader, S. A., et al. 2005. IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-gamma responses if IL-12p70 is available. J. Immunol. 175:788-795.
25. Landegren, U. 1984. Measurement of cell numbers by means of the endogenous enzyme hexosaminidase. Applications to detection of lymphokines and cell surface antigens. J. Immunol. Methods 67:379-388.
26. Lockhart, E., A. M. Green, and J. L. Flynn. 2006. IL-17 production is dominated by γδ T cells rather than CD4 T cells during Mycobacterium tuberculosis infection. J. Immunol. 177:4662-4669.
27. Miller, E. A., and J. D. Ernst. 2009. Anti-TNF immunotherapy and tuberculosis reactivation: another mechanism revealed. J. Clin. Invest. 119:1079-1082.
28. Miossec, P., T. Korn, and V. K. Kuchroo. 2009. Interleukin-17 and type 17 helper T cells. N. Engl. J. Med. 361:888-898.
29. Okamoto Yoshida, Y., et al. 2010. Essential role of IL-17A in the formation of a mycobacterial infection-induced granuloma in the lung. J. Immunol. 184:4414-4422.
30. Parham, C., et al. 2002. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rβ1 and a novel cytokine receptor subunit, IL-23R. J. Immunol. 168:5699-5708.
31. Pedraza-Sánchez, S., et al. 2010. Bacille Calmette-Guérin infection and disease with fatal outcome associated with a point mutation in the interleukin-12/interleukin-23 receptor beta-1 chain in two Mexican families. Int. J. Infect. Dis. 14(Suppl. 3):3256-e260.
32. Sutton, C. E., et al. 2009. Interleukin-1 and IL-23 induce innate IL-17 production from γδ T cells, amplifying Th17 responses and autoimmunity. Immunity 31:331-341.
33. Tanghe, A., et al. 2001. Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting. Infect. Immun. 69:3041-3047.
34. Umemura, M., et al. 2007. IL-17-mediated regulation of innate and acquired immune response against pulmonary Mycobacterium bovis bacille Calmette-Guerin infection. J. Immunol. 178:3786-3796.
35. Uyttenhove, C., B. Arendse, V. Stroobant, F. Brombacher, and J. Van Snick. 2004. Development of an anti-IL-12 p40 auto-vaccine: protection in experimental autoimmune encephalitis at the expense of increased sensitivity to infection. Eur. J. Immunol. 34:3572-3581.
36. Uyttenhove, C., R. J. Simpson, and J. Van Snick. 1988. Functional and structural characterization of P40, a mouse glycoprotein with T-cell growth factor activity. Proc. Natl. Acad. Sci. U. S. A. 85:6934-6938.
37. van de Vosse, E., et al. 2010. Mycobacterium bovis BCG-itis and cervical lymphadenitis due to Salmonella enteritidis in a patient with complete interleukin-12/-23 receptor beta1 deficiency. Infection 38:128-130.
38. Van Snick, J., et al. 1986. Purification and NH2-terminal amino acid sequence of a T-cell-derived lymphokine with growth factor activity for B-cell hybridomas. Proc. Natl. Acad. Sci. U. S. A. 83:9679-9683.
39. Veldhoen, M., R. J. Hocking, C. J. Atkins, R. M. Locksley, and B. Stockinger. 2006. TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24:179-189. (Pubitemid 43214587)
40. Wakeham, J., et al. 1998. Lack of both types 1 and 2 cytokines, tissue inflammatory responses, and immune protection during pulmonary infection by Mycobacterium bovis bacille Calmette-Guérin in IL-12 deficient mice. J. Immunol. 160:6101-6111.
41. Wozniak, T. M., A. A. Ryan, and W. J. Britton. 2006. Interleukin-23 restores immunity to Mycobacterium tuberculosis infection in IL-12p40 deficient mice and is not required for the development of IL-17 secreting T cell responses. J. Immunol. 177:8684-8692.
42. Wozniak, T. M., A. A. Ryan, J. A. Triccas, and W. J. Britton. 2006. Plasmid interleukin-23 (IL-23) but not plasmid IL-27 enhances the protective efficacy of a DNA vaccine against Mycobacterium tuberculosis infection. Infect. Immun. 74:557-565.
43. Wozniak, T. M., B. M. Saunders, A. A. Ryan, and W. J. Britton. 2010. Mycobacterium bovis BCG-specific Th17 cells confer partial protection against Mycobacterium tuberculosis infection in the absence of gamma interferon. Infect. Immun. 78:4187-4194.
44. Wu, C., J. Ferrante, M. K. Gately, and J. Magram. 1997. Characterization of IL-12 receptor β1 chain (IL-12Rβ1)-deficient mice: IL-12Rβ1 is an essential component of functional mouse IL-12 receptor. J. Immunol. 159:1658-1665. (Pubitemid 127484149)